MTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 1, 2013, Pages 42-56

  Barthélémy, Philippe ^a   Hoch, Benjamin ^b   Chevreau, Christine ^c   Joly, Florence ^d   Laguerre, Brigitte ^e   Lokiec, François ^f   Duclos, Brigitte ^a  

^a HÔpital de Hautepierre ^*  (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CHU CÔTE DE NACRE   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f CENTRE RENÉ HUGUENIN   (France)

Author keywords

Everolimus; Kidney cancer; MTOR inhibitors; Temsirolimus

Indexed keywords

ALPHA INTERFERON; APREPITANT; AXITINIB; BERGAMOTTIN; BEVACIZUMAB; BUPRENORPHINE; CHLORAMPHENICOL; CIMETIDINE; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 3A4; DESIPRAMINE; DILTIAZEM; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; INITIATION FACTOR 4E BINDING PROTEIN 1; ITRACONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAPAMYCIN; RITONAVIR; S6 KINASE; SORAFENIB; SUNITINIB; TELITHROMYCIN; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; VERAPAMIL;

ADVANCED CANCER; AGE; ANEMIA; ANOREXIA; ANTIFUNGAL RESISTANCE; ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; COMORBIDITY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY METASTASIS; LIVER DYSFUNCTION; LUNG FUNCTION TEST; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NONHUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN SYNTHESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; STREPTOMYCES HYGROSCOPICUS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT INDICATION;

EVEROLIMUS; KIDNEY CANCER; MTOR INHIBITORS; TEMSIROLIMUS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84884167903     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.02.006     Document Type: Review

References (78)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. The European Journal of Cancer 2010, 46:765-781.
2. Corradetti M.N., Guan K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene 2006, 25:6347-6360.
3. Carmeliet P. Angiogenesis in health and disease. Nature Medicine 2003, 9:653-660.
4. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. Journal of Clinical Oncology 2005, 23:1028-1043.
5. Amato R.J. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Annals of Oncology 2005, 16:7-15.
6. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer 2002, 2:673-682.
7. Mamane Y., Petroulakis E., LeBacquer O., Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006, 25:6416-6422.
8. Li W., Sumpio B.E. Strain-induced vascular endothelial cell proliferation requires PI3K-dependent mTOR-4E-BP1 signal pathway. American Journal of Physiology: Heart and Circulatory Physiology 2005, 288:H1591-H1597.
9. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and Cellular Biology 2002, 22:7004-7014.
10. Robb V.A., Karbowniczek M., Klein-Szanto A.J., Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. Journal of Urology 2007, 177:346-352.
11. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
12. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
13. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 2007, 356:2271-2281.
14. Vézina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. Journal of Antibiotics (Tokyo) 1975, 28:721-726.
15. Sehgal S.N., Baker H., Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. Journal of Antibiotics (Tokyo) 1975, 28:727-732.
16. Sehgal S.N., Molnar-Kimber K., Ocain T.D., Weichman B.M. Rapamycin: a novel immunosuppressive macrolide. Medicinal Research Reviews 1994, 14:1-22.
17. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nature Reviews Cancer 2004, 4:335-348.
18. Luan F.L., Ding R., Sharma V.K., Chon W.J., Lagman M., Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney International 2003, 63:917-926.
19. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology 2009, 27:2278-2287.
20. Boni J.P., Hug B., Leister C., Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Seminars in Oncology 2009, 36(Suppl. 3):S18-S25.
21. Podsypanina K., Lee R.T., Politis C., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10320-10325.
22. Houghton P.J. Everolimus. Clinical Cancer Research 2010, 16:1368-1372.
23. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
24. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clinical Cancer Research 2007, 13:3109-3114.
25. Voss M.H., Molina A.M., Motzer R.J. mTOR inhibitors in advanced renal cell carcinoma. Hematology/Oncology Clinics of North America 2011, 25:835-852.
26. Crowe A., Bruelisauer A., Duerr L., Guntz P., Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metabolism and Disposition 1999, 27:627-632.
27. Kirchner G.I., Meier-Wiedenbach I., Manns M.P. Clinical pharmacokinetics of everolimus. Clinical Pharmacokinetics 2004, 43:83-95.
28. Torisel [package insert] 2008, Wyeth Pharmaceuticals, Inc, Philadelphia, PA.
29. O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. Journal of Clinical Oncology 2008, 26:1588-1595.
30. Boni J.P., Leister C., Burns J., Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. British Journal of Cancer 2008, 98:1797-1802.
31. Kovarik J.M., Sabia H.D., Figueiredo J., et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clinical Pharmacology and Therapeutics 2001, 70:425-430.
32. Lunardi G., Vannozzi M.O., Armirotti A., Nicodemo M., Venturini M., Cavallini L. Temsirolimus in patients with renal cancer on hemodialysis. Journal of Clinical Oncology 2008, 26:5652-5653.
33. Boni J., Abbas R., Leister C., et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemotherapy and Pharmacology 2009, 64:263-270.
34. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology 1999, 17:2530-2540.
35. Négrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Annals of Oncology 2002, 13:1460-1468.
36. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 2007, 11:115-124.
37. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543-550.
38. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of Clinical Oncology 2009, 27:5794-5799.
39. Manola J., Royston P., Elson P., et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clinical Cancer Research 2011, 17:5443-5450.
40. Escudier B., Albiges L., Blesius A., Loriot Y., Massard C., Fizazi K. How to select targeted therapy in renal cell cancer. Annals of Oncology 2010, 21(suppl.7):vii59-vii62.
41. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology 2004, 22:909-918.
42. Amato R.J., Jac J., Giessinger S., Saxena S., Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446.
43. Rini B.I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
44. Hutson T., Escudier B., Esteban E., et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. ESMO Congress 2012, abstr LBA22-PR.
45. Figlin R.A., Calvo E., Motzer R.J., et al. Everolimus in metastatic renal cell carcinoma (mRCC): subgroup analysis of patients (pts) with one versus two prior inhibitor (VEGFR-TKI) therapies enrolled in the phase III vascular endothelial growth factor receptor tyrosine kinase RECORD-1 study. Journal of Clinical Oncology 2011, 29(Suppl. 7). abstr 304.
46. Dutcher J.P., de Souza P., McDermott D., et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncology 2009, 26:202-209.
47. Motzer R.J., Bacik J., Mariani T., Russo P., Mazumdar M., Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. Journal of Clinical Oncology 2002, 20:2376-2381.
48. Grünwald V., Karakiewicz P.I., Bavbek S.E., et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer 2012, 48:324-332.
49. Choueiri T.K., Plantade A., Elson P., et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Journal of Clinical Oncology 2008, 26:127-131.
50. Ravaud A., Oudard S., Gravis-Mescam G., et al. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). Journal of Clinical Oncology 2009, 27(suppl). abstr 5146.
51. Caglio S., Slimane K., May C., Escudier B. Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma. Journal of Clinical Oncology 2010, 28(suppl). abstr TPS234.
52. Maj-Hes A., Elaidi R.T., Medioni J., et al. What is the benefit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI?. Journal of Clinical Oncology 2012, 30(Suppl. 5). abstr 442.
53. Carew J.S., Kelly K.R. Mechanisms of mTOR inhibitor resistance in cancer therapy. Targeted Oncology 2011, 6:17-27.
54. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 2007, 67:10804-10812.
55. Goodwin P.J., Stambolic V., Lemieux J., et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment 2011, 126:215-220.
56. Patel P.H., Senico P.L., Curiel R.E., Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clinical Genitourinary Cancer 2009, 7:24-27.
57. Feldman D.R., Baum M.S., Ginsberg M.S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2009, 27:1432-1439.
58. Molina A.M., Feldman D.R., Voss M.H., et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012, 118:1868-1876.
59. Merchan J.R., Liu G., Fitch T., et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Journal of Clinical Oncology 2007, 25(Suppl. 18). abstr 5034.
60. Zafar Y., Bendell J., Lager J., et al. Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. Journal of Clinical Oncology 2006, 24(Suppl. 18). abstr 3097.
61. Whorf R.C., Hainsworth J.D., Spigel D.R., et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). Journal of Clinical Oncology 2008, 26(Suppl). abstr 5010.
62. Négrier S., Gravis G., Pérol D., et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. The Lancet Oncology 2011, 12:673-680.
63. Rini B.I., Bellmunt J., Clancy J., Wang K., Niethammer A., Escudier B. Randomized Phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. ESMO Congress 2012, abstr LBA21-PR.
64. Ravaud A., Barrios C., Anak O., et al. Randomized phase II study of first-line everolimus (EVE)+bevacizumab (BEV) versus interferon alfa-2a (IFN)+BEV in patients (pts) with metastatic renal cell carcinoma (mRCC): RECORD-2. ESMO Congress 2012, abstr 783O.
65. Porta C., Szczylik C., Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Critical Reviews in Oncology/Hematology 2012, 82:323-337.
66. Maroto J.P., Hudes G., Dutcher J.P., et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. Journal of Clinical Oncology 2011, 29:1750-1756.
67. Bellmunt J., Szczylik C., Feingold J., Strahs A., Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology 2008, 19:1387-1392.
68. White D.A., Camus P., Endo M., et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. American Journal of Respiratory and Critical Care Medicine 2010, 182:396-403.
69. Albiges L., Chamming's F., Duclos B., et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Annals of Oncology 2012, June 11 [Epub ahead of print].
70. Li J., DeFea K., Roth R.A. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. The Journal of Biological Chemistry 1999, 274:9351-9356.
71. Ozes O.N., Akca H., Mayo L.D., et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:4640-4645.
72. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. The Journal of Cell Biology 2004, 167:399-403.
73. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
74. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine 2007, 356:125-134.
75. Sibaud V., Garrido-Stowhas I., Cottura E., Chevreau C. Dermatologic side effects induced by new angiogenesis inhibitors. Bulletin du Cancer 2011, 98:1221-1229. [article in French].
76. Partridge A.H., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute 2002, 94:652-661.
77. Molina A.M., Motzer R.J. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011, 16(Suppl. 2):45-50.
78. Escudier B., Eisen T., Porta C., et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012, 23(Suppl. 7):vii65-vii71.